Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:1887-1892

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weisz, A.
Right arrow Articles by Flugelman, M. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weisz, A.
Right arrow Articles by Flugelman, M. Y.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Angiogenesis
Right arrow Gene therapy

(Circulation. 2001;103:1887.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Increased Vascular Endothelial Growth Factor 165 Binding to Kinase Insert Domain–Containing Receptor After Infection of Human Endothelial Cells by Recombinant Adenovirus Encoding the Vegf165 Gene

Anat Weisz, PhD; Belly Koren, MSc; Tzafra Cohen, PhD; Gera Neufeld, PhD; Tamar Kleinberger, PhD; Basil S. Lewis, MD, FRCP; Moshe Y. Flugelman, MD

From the Laboratory of Molecular and Cellular Cardiology, Department of Cardiology, Lady Davis Carmel Medical Center (A.W., B.K., B.S.L., M.Y.F.); the Unit of Molecular Microbiology (T.K.), Bruce Rappaport School of Medicine; and the Faculty of Biology (T.C., G.N.), Technion-IIT, Haifa, Israel.

Correspondence to Moshe Y. Flugelman, MD, Department of Cardiology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel 34632. E-mail myf{at}tx.technion.ac.il

Background—The angiogenic effect of vascular endothelial growth factor (VEGF165) is mediated mainly through the high-affinity tyrosine kinase receptor VEGF-R2 (KDR/flk-1). This study examined the effects of VEGF overexpression by primary human endothelial cells (ECs), which do not express VEGF under physiological conditions, on cell proliferation, VEGF binding to the kinase insert domain–containing receptor (KDR), and KDR expression.

Methods and Results—Human primary ECs and SMCs were infected by recombinant adenoviral vector encoding VEGF165 (rAdVEGF). Proliferation rate, bromodeoxyuridine incorporation, 125I-labeled VEGF165 binding to the KDR receptor, and KDR expression were tested in the infected cells and in cells supplemented with VEGF protein. Enhanced proliferation and a significant increase in 125I-VEGF165 binding to the KDR receptor were induced by rAdVEGF infection of ECs (autocrine effect) as well as by addition of recombinant VEGF165 to noninfected cells. Infection of ECs by rAdVEGF led to posttranscriptional upregulation of the KDR receptor, whereas KDR mRNA expression levels remained unchanged. Similar effects were observed with supplemented recombinant VEGF165 to noninfected ECs; nevertheless, this phenomenon occurred only with high VEGF165 concentrations (10 ng/mL).

Conclusions—The effect of VEGF165 on proliferation and upregulation of KDR receptor expression demonstrated an autocrine phenomenon of EC sensitization. The fact that high concentrations of VEGF may be achieved in vivo by local continuous overexpression of VEGF165 by gene transfer emphasizes the potential advantage of gene transfer over protein supplementation for therapeutic angiogenesis.


Key Words: genes • cells • viruses




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
Y. Wang, Y. Zheng, W. Zhang, H. Yu, K. Lou, Y. Zhang, Q. Qin, B. Zhao, Y. Yang, and R. Hui
Polymorphisms of KDR Gene Are Associated With Coronary Heart Disease
J. Am. Coll. Cardiol., August 21, 2007; 50(8): 760 - 767.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M A J Herve, G Meduri, F G Petit, T S Domet, G Lazennec, S Mourah, and M Perrot-Applanat
Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus
J. Endocrinol., January 1, 2006; 188(1): 91 - 99.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Rutanen, P. Leppanen, T. T Tuomisto, T. T Rissanen, M. O Hiltunen, I. Vajanto, M. Niemi, T. Hakkinen, K. Karkola, S. A Stacker, et al.
Vascular endothelial growth factor-D expression in human atherosclerotic lesions
Cardiovasc Res, October 1, 2003; 59(4): 971 - 979.
[Abstract] [Full Text] [PDF]